AgeX Therapeutics, Inc., a biotechnology company developing therapeutics for human aging and regeneration, announced today the online publication of data relating to regeneration, aging, and cancer in bioRxiv. The paper titled “Differential Expression of α, β, and γ Protocadherin Isoforms During Differentiation, Aging, and Cancer” presents for the first time data relating to mechanisms cells may use in the process of regeneration. The paper discloses alterations in certain genes that may prevent regeneration from occurring in adult humans. It also provides evidence that the family of genes may be involved in a wide array of human cancers.
“We believe these results have significant importance for researchers working not only in the field of aging research, but the field of cancer research as well,” said , CEO of AgeX. “As a result, we published this data as a non-peer reviewed preprint to accelerate the timeline during which other scientists can see and test the results in their own laboratories. We plan to implement the findings in our induced Tissue Regeneration (iTR) program, and as a result, have filed a series of relevant patent applications. We plan to publish the results at a later time in a peer-reviewed format.”
Authors on the paper include: Michael D. West, Ivan Labat, Jie Li, Pam Sim, Jeffrey Janus, and Hal Sternberg of AgeX; Hayley Mangelson, Shawn Sullivan, and Ivan Liachko of Phase Genomics, Inc.; Paul Labhart, Maddy Craske, and Brian Egan of Active Motif, Inc.; Karen B. Chapman of Eclipse Bioinnovations, Inc.; of Juvenescence Ltd.; and Dana Larocca of DC Biotechnology. The article is available for viewing here. A video explaining the results is available for viewing here.
ABOUT AGEX THERAPEUTICS
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing innovative regenerative therapeutics to treat human diseases to increase healthspan and combat the effects of aging. AgeX’s PureStem® and UniverCyte™ manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeX’s revolutionary longevity platform induced Tissue Regeneration (iTR™) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. HyStem® is AgeX’s delivery technology intended to stably engraft PureStem® derived cell therapies in the body. AgeX is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms and therapy product candidates.
For more information, please visit www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.
Link to the Business Wire press release found here.